- Home
- CVAC vs IOVA Comparison
CVAC vs IOVA Comparison
Compare CVAC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- IOVA
- Stock Information
- Founded
- CVAC 2000
- IOVA 2007
- Country
- CVAC Germany
- IOVA United States
- Employees
- CVAC N/A
- IOVA N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVAC Health Care
- IOVA Health Care
- Exchange
- CVAC Nasdaq
- IOVA Nasdaq
- Market Cap
- CVAC 1.2B
- IOVA 975.1M
- IPO Year
- CVAC 2020
- IOVA N/A
- Fundamental
- Price
- CVAC $5.34
- IOVA $2.55
- Analyst Decision
- CVAC Hold
- IOVA Buy
- Analyst Count
- CVAC 3
- IOVA 11
- Target Price
- CVAC $6.83
- IOVA $10.50
- AVG Volume (30 Days)
- CVAC 574.2K
- IOVA 20.9M
- Earning Date
- CVAC 11-12-2025
- IOVA 11-06-2025
- Dividend Yield
- CVAC N/A
- IOVA N/A
- EPS Growth
- CVAC N/A
- IOVA N/A
- EPS
- CVAC 1.01
- IOVA N/A
- Revenue
- CVAC $599,540,810.00
- IOVA $250,425,000.00
- Revenue This Year
- CVAC N/A
- IOVA $65.15
- Revenue Next Year
- CVAC $23.40
- IOVA $58.47
- P/E Ratio
- CVAC $5.32
- IOVA N/A
- Revenue Growth
- CVAC 675.15
- IOVA 175.62
- 52 Week Low
- CVAC $2.37
- IOVA $1.64
- 52 Week High
- CVAC $5.72
- IOVA $10.47
- Technical
- Relative Strength Index (RSI)
- CVAC 51.18
- IOVA 61.98
- Support Level
- CVAC $5.17
- IOVA $2.08
- Resistance Level
- CVAC $5.41
- IOVA $2.74
- Average True Range (ATR)
- CVAC 0.05
- IOVA 0.21
- MACD
- CVAC -0.00
- IOVA 0.07
- Stochastic Oscillator
- CVAC 70.82
- IOVA 80.61
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.